Study Shows Medtronic (MDT) Microdebrider Turbinoplasty is a Significantly More Effective, Long-Term Treatment Than Coblation Radiofrequency for Nasal Obstructions
More News related to MDT
- Medtronic Receives President's "E" Award in Recognition of Its Support of U.S. Exports
- Notable Analyst Rating Changes 11/5: PALM, VALE, TRW, ONNN, MDT, SPWRA Upgraded; CMCSA, ARO, DPTR, GRMN TEX Downgraded
- Credit Suisse Upgrades Medtronic (MDT) to Outperform
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- CORRECTION FROM SOURCE: Saskatchewan Roughrider John Chick Shows London Children that Diabetes Doesn't Have to Prevent Them from Reaching Their Dreams
Medtronic (NYSE: MDT) announced that results of a study published in the February issue of the Laryngoscope were favorable toward the use of Medtronic's Straightshot(R) M4 Microdebrider for powered inferior turbinoplasty. Written by Liu et al from Taipei Medical University, "Microdebrider-Assisted Versus Radiofrequency-Assisted Turbinoplasty," states that patients treated with Medtronic's microdebrider experienced significantly better long-term outcomes than those who received treatment with a Coblation(R) radiofrequency device in what is the first three-year study directly comparing long-term efficacy of the two techniques.
"This study adds significant weight to the argument that RF treatments with Coblation aimed at the inferior turbinates are ineffective long term and put the patient's nasal mucosa at risk," says Scott Carpenter, senior product manager for ENT Powered Systems, part of the Surgical Technologies business at Medtronic.
See full press release here.
Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.45Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
